A variety of large-scale pharmacogenomic data, such as perturbation experiments and sensitivity profiles, enable the systematical identification of drug mechanism of actions (MoAs), which is a crucial task in the era of precision medicine. However, integrating these complementary pharmacogenomic datasets is inherently challenging due to the wild heterogeneity, high-dimensionality and noisy natu...

Pharmacogenomics is one of the fi rst clinical applications of the postgenomic era. It promises personalized medicine rather than the established " one size fi ts all " approach to drugs and dosages. The expected reduction in trial and error should ultimately lead to more effi cient and safer drug therapy. In recent years, commercially available pharmacogenomic tests have been approved by the F...

Pharmacogenomic testing can be integrated into modern mental health practices to help select psychotropic drugs for individuals who have failed first-line evidence-based treatments. This can be done by the process of "equipoise"-namely, balancing the weight of all available evidence. That evidence now includes not only diagnosis-specific treatment guidelines and "personalized" patient informati...

Pharmacists must consider all factors when dosing medication for a patient. Until recently, however, one key piece to this puzzle was missing--genetics. This invisible piece of the puzzle can now be utilized with pharmacogenetic testing. By using pharmacogenetic testing, the compounding pharmacist will be able to better predict disease risk as well as the pharmacodynamic and pharmacokinetic act...

Few would argue that the ability to match individual patients with the safest and most effective drugs and doses would be a major advance for clinical medicine. But while clinicians have been reluctant to routinely use pharmacogenomic analyses to guide their prescribing practices, pharmacy benefit managers and drugstores are proceeding with major pharmacogenetic initiatives.

Pharmacogenomic testing in mental health has not yet reached its full potential. An important reason for this involves differentiating individual gene testing (IGT) from a combinatorial pharmacogenomic (CPGx) approach. With IGT, any given gene reveals specific information that may, in turn, pertain to a smaller number of medications. CPGx approaches attempt to encompass more complete genomic in...